A randomized evaluation of the treatment of post-COVID syndrome
Medical recommendations are based on high-quality evidence, which is ideally generated by randomized controlled trials (RCTs). In order to collect sufficient data to assess a therapy, a new RCT is usually set up for each new therapeutic approach. This procedure is associated with long implementation times, high costs and a lack of flexibility. Adaptive platform studies are considered a practicable solution to these problems. The “National Pandemic Cohort Network – Therapeutic Intervention Platform” (NAPKON-TIP) aims to establish an infrastructure for adaptive clinical platform studies in Germany. NAPKON-TIP is part of the Network University Medicine (NUM) infrastructure.
Together with renowned university project partners, cosinuss° contributes to the first use case of the NAPKON-TIP infrastructure entitled “Randomized adaptive assessment of Post-COVID-Syndrom treatments_Reducing Inflammatory Activity in Patients with post COVID Syndrome (RAPID_REVIVE)”.
Find out more about the study here: RAPID_REVIVE
